Active	Status	Sponsor type	Region	Phase	Filter
12 Active 15 Inactive 27 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Johnson, Michelle J
QTX3034-001, NCT06227377: QTX3034 in Patients With KRAS G12D Mutation	Recruiting	1	250	US	QTX3034, Cetuximab	Quanta Therapeutics	Solid Tumors	04/27	04/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Johnson, Michelle J
QTX3034-001, NCT06227377: QTX3034 in Patients With KRAS G12D Mutation	Recruiting	1	250	US	QTX3034, Cetuximab	Quanta Therapeutics	Solid Tumors	04/27	04/27